# Andreas Schneeweiß

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/andreas-schneewei/

## Facts

| Field | Value |
| --- | --- |
| Citations | 54,214 |
| Field | Breast Cancer Treatment Studies |
| h-index | 101 |
| i10-index | 491 |
| Last Known Institution | German Cancer Research Center |
| OpenAlex ID | https://openalex.org/A5089392438 |
| ORCID iD | https://orcid.org/0000-0002-2429-4512 |
| Works | 1,648 |

## Researcher papers

- [Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-emtansine-for-residual-invasive-her2-positive-breast-cancer/)
- [Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy](https://scholariq.org/papers/tumour-infiltrating-lymphocytes-and-prognosis-in-different-subtypes-of-breast/)
- [Large-scale genotyping identifies 41 new loci associated with breast cancer risk](https://scholariq.org/papers/large-scale-genotyping-identifies-41-new-loci-associated-with-breast-cancer-risk/)
- [Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay](https://scholariq.org/papers/identification-of-a-population-of-blood-circulating-tumor-cells-from-breast/)
- [Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial](https://scholariq.org/papers/neoadjuvant-carboplatin-in-patients-with-triple-negative-and-her2-positive-early/)
- [Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pertuzumab-trastuzumab-and-docetaxel-for-her2-positive-metastatic-breast-cancer/)
- [Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer](https://scholariq.org/papers/primary-results-from-impassion131-a-double-blind-placebo-controlled-randomised/)
- [A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study](https://scholariq.org/papers/a-randomised-phase-ii-study-investigating-durvalumab-in-addition-to-an/)
- [MicroRNA Related Polymorphisms and Breast Cancer Risk](https://scholariq.org/papers/microrna-related-polymorphisms-and-breast-cancer-risk/)
- [Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials](https://scholariq.org/papers/clinical-and-molecular-characteristics-of-her2-low-positive-breast-cancer-pooled/)
- [Identification of Novel Genetic Markers of Breast Cancer Survival](https://scholariq.org/papers/identification-of-novel-genetic-markers-of-breast-cancer-survival/)
- [13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus - Opinion of a German Team of Experts (Zurich 2013)](https://scholariq.org/papers/13th-st-gallen-international-breast-cancer-conference-2013-primary-therapy-of/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [German Cancer Research Center](https://scholariq.org/institutions/german-cancer-research-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.